why choose us

First received: December 09, 2022

Clinical Trial: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refrac

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients:Patients with advanced breast cancer that has become worse after taking palbociclib alonePatients with cancers that have an abnormality in a gene called the "retinoblastoma gene".

Read more